Tekturna
Product Images NDC 54868-6042

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Tekturna (NDC 54868-6042). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Physicians Total Care, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Of 150 mg Package Label (5772)

This is information regarding medication TEKTURNA 156HG, distributed by PHYSICIANS TOTAL CARE with NDC number 54868-5772-0. The lot number is 060 with an expiration date of 61/60. The manufacturer appears to be NOVARTIS.*

FDA Label Image

Image Of 300 mg Package Label (6042)

This is a prescription drug label for Tekturna tablets, distributed by Physicians Total Care. The drug has a strength of 306 milligrams and is packaged in a bottle with lot number 6600 and expiration date 61/60. The label also includes TSA and NDC numbers. The last line of text is not clear and seems to be a random combination of letters and numbers.*

FDA Label Image

Aliskiren Hemifumarate Structural Formula (Tekturna 01)

FDA Label Image

Figure 1: The Impact Of Co-administered Drugs On The Pharmacokinetics Of Aliskiren. (Tekturna 02)

This appears to be a table showing the impact of co-administered drugs on the pharmacokinetics (PK) of aliskiren, along with recommendations for dose adjustment. Certain drugs, such as Cyclosporine and Ketoconazole should be avoided. Other medications, such as Hydrochlorothiazide, Ramipril, and Metformin, do not require a dose adjustment. The table also displays a "Change relative to aliskiren alone" column, which may refer to the fold change observed in the presence of the co-administered drugs. However, one section of the text is not clearly readable.*

FDA Label Image

Figure 2: The Impact Of Aliskiren On The Pharmacokinetics Of Co-administered Drugs. (Tekturna 03)

This text is an evaluation of the impact of aliskiren on the pharmacokinetics of co-administered drugs. It presents a table with various drugs classified into two categories - antihypertensives and others. The table shows the PK fold changes and 90% recommendations for each drug, as well as changes relative to the interacting drug alone. The conclusion is that most drugs do not require a dose adjustment when co-administered with aliskiren, except for indapamide, which should be monitored closely.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.